Navigation Links
Study challenges baby formula claim
Date:7/14/2011

Despite the formula being recommended in public health guidelines set out by the Australasian Society of Clinical Immunology and Allergy, the new study, published online in the Journal of Allergy and Clinical Immunology, found there was no benefit in using hypoallergenic (partially hydrolysed whey) formula to prevent allergies in high-risk infants up to seven years of age, compared to a conventional cow's milk based formula.

The trial, which is one the largest to test the effect of hypoallergenic baby formula, involved 620 infants and assessed whether using the formula decreased the risk of allergy in later life.

Infants in the study were given either hypoallergenic, cow's milk or soy formula after the cessation of breastfeeding. Allergy testing was undertaken at six, 12 and 24 months and children were followed up again at six or seven years of age.

Lead authors David Hill, a Senior Consultant Allergist at the Murdoch Childrens Research Institute and Adrian Lowe, a research fellow at the Murdoch Childrens Research Institute and the Centre for MEGA Epidemiology, the University of Melbourne said their findings did not support the recommendations that hypoallergenic formula should be used after breast feeding as a preventive strategy for infants at high risk of allergenic disease.

"In our study of high risk children, this 'hypoallergenic' formula did not show any beneficial effect, when compared with a normal cows' milk based formula, for the prevention childhood eczema, asthma or hay fever up to seven years of age," Dr Lowe said.

Dr Hill said: "Our findings do not support the role of hypoallergenic formula for the prevention of allergic disease. Families at high risk of allergy should continue to be encouraged to breast feed for the many known benefits associated with breastfeeding."


'/>"/>

Contact: Charlotte Crawford
charlotte.crawford@unimelb.edu.au
University of Melbourne
Source:Eurekalert

Page: 1

Related biology news :

1. Study explains why men are at higher risk for stomach cancer
2. First study into GM Atlantic salmon mating reveals danger of escape to wild gene pool
3. Your mother was right: Study shows good posture makes you tougher
4. Researchers study pesticide pathways into the atmosphere
5. Scleroderma study identifies roadblocks to employment
6. Study: People at risk for panic buffered from stressor by high levels of physical activity
7. UCI study points to new means of overcoming antiviral resistance in influenza
8. Owl study expands understanding of human stereovision
9. Virginia Tech Coal and Energy Center selected for study of CO2 injection into storage reservoirs
10. Large human study links phthalates, BPA and thyroid hormone levels
11. University of Houston researcher an author of multi-institutional genetic study of ovarian cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/9/2017)... 2017 The biomass boiler market report by ... boiler market globally in terms of revenue (US$ Mn) ... market for biomass boilers has been segmented on the ... country/region. The market based on feedstock type, has been ... & energy crops, urban residues, and others. On the ...
(Date:2/8/2017)... 7, 2017 Report Highlights The ... from $8.3 billion in 2016 at a compound annual ... Report Includes - An overview of the global ... with data from 2015 and 2016, and projections of ... of the market on the basis of product type, ...
(Date:2/3/2017)... 3, 2017  Texas Biomedical Research Institute announced that its ... Schlesinger as the Institute,s new President and CEO. Dr. ... 31, 2017. He is currently the Chair of the Department ... for Microbial Interface Biology at Ohio State University. ... President and CEO of Texas Biomed," said Dr. James ...
Breaking Biology News(10 mins):
(Date:2/23/2017)... SAN RAFAEL, Calif., Feb. 23, 2017 ... of U.S. dollars, except per share data, unaudited)Three Months ... ChangeTotal BioMarin Revenue $ ...     22832%$ 1,117$   89026%Aldurazyme Net Product Revenue ... 906538%34823946%Naglazyme Net Product Revenue  ...
(Date:2/23/2017)... 23, 2017 /PRNewswire/ - The Fight Against Cancer Innovation ... (OICR) are pleased to report that Fusion Pharmaceuticals Inc. ... Johnson & Johnson Innovation – JJDC, Inc. (JJDC) as ... HealthCap, TPG Biotechnology Partners, and Genesys Capital, as well ... ...
(Date:2/23/2017)... ATLANTA , Feb. 23, 2017  In Atlanta, it ... art, fashion, and culture intertwine to create an expressive and ... often reflect this energy and contribute to it. ... , Hair Fairies seeks to carry on that ... The Atlanta salon is the newest ...
(Date:2/23/2017)... ROCHESTER, Minn. , Feb. 23, 2017 /PRNewswire/ ... a new product line of oncolytic vaccinia viruses ... Genelux Corporation as part of Genelux,s proprietary, vaccinia ... "We are excited to enter into a partnership ... time, selected oncolytic vaccinia viruses for use in ...
Breaking Biology Technology: